Trulieve Q3 revenue falls 20% to $230 million; net income of $0.9 million
Trulieve reported third-quarter 2026 revenue of $230 million, down 20% from $288 million a year earlier, and net income attributable to common shareholders of $0.9 million, compared with a loss of $26.8 million in the same quarter of 2025. The company said Q3 2026 includes only its medical operations, while prior periods include Harvest's mixed medical and adult-use results, so the comparison is not like-for-like. Nine-month results show a net loss of $402.7 million, driven mainly by a $403.3 million loss on the June 2026 deconsolidation of Harvest, and the filing gives no financial guidance.
Key points
- Revenue of $230 million, down 20% from $288 million; gross margin of 64% versus 59% a year earlier.
- Net income attributable to common shareholders of $0.9 million, or $0.00 per diluted share, versus a loss of $26.8 million, or $0.14 per share, in Q3 2025.
- Adjusted EBITDA of $89 million (39% of revenue), down from $103 million; cash and cash equivalents of $326.7 million at September 30, 2026.
- Nine-month net loss of $402.7 million, including a $403.3 million loss on deconsolidation of Harvest operations recorded in the period.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.